arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Jazz Pharmaceuticals plc

JAZZ
$227.29 ▼ -7.28 (-3.10%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Jazz Pharmaceuticals plc faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $13.9B
Dividend Yield —
Revenue Growth 4.9% ↘
Op. Margin -10.1% ↘
ROIC -3.5% ↘
FCF / Share $21.27 ↘
Trailing P/E —
Price / Book 3.2x
FCF Yield 9.4%
Debt / Equity 1.24
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.27B
↑ +4.9% —
Net Income Profit after all expenses
$-356.15M
↓ -163.6% —
Operating Margin Operating profit as % of sales
-10.1%
↓ -157.2% 15th
FCF / Share Free cash flow per share
$21.27
↓ -3.1% —
Long-Term Debt Long-term obligations
$5.36B
↓ -12.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
42
Returns →
35
Financial Health ↓
33
Cash Quality ↓
4

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 69 quarters